Welcome. This is Thomas Hartung from John Hopkins again. Welcome to the next module. And in this module we're going to talk about biometry. You could say in a simplification that toxicology for the 21st century, evidence-based toxicology, is a marriage of biometric approaches and the classical biomedical tools. Because we are bringing in assessment tools, we are bringing in a thorough analysis of data and of our processes to show that something is factual evidence or not. And for this reason, Andre Kleensang who's giving this course, he's part of our team, and a biostatistician, he's showing you what our critical tools from biostatistics and bioinformatics, which are used in evidence-based approaches. So I hope you enjoy this very short summary of a very complicated topic, which will give you a feeling for how these things integrate into the evidence-based toxicology as it is forming at the moment. The last lesson, which is the second in this module, is then on the perspectives of evidence-based toxicology. You have learned in this course that we are actually having only a pretty short history of about 15 years. This short history is a lot of trying, accumulating people, getting enthusiasm by researchers, and we were very excited that more and more people have joined in. However, this is reflecting at the moment mainly transatlantic organizations. And so it is the US, Canada, and it is the European side. We're at the moment trying to expand this to a global perspective. Because a global industry requires global approaches to their regulation, requires global approaches in order to insure the safety of substances. So, for this reason, South America, the Far East, but also the other areas of the world, at the moment, in focus to get engaged in this movement. You've also seen that evidence-based toxicology so far is not addressing all industrial sectors to the same extent. It is, in part, the food safety on the European side which is a driving force. European food safety authority is taking a clear lead. And it's mainly industrial chemicals on the US side with some interest by the FDA again into food which is spurring the development of evidence-based toxicology. But there are so many other areas where safety is established with systematic reviews could help. And last but not least, why stop at toxicology? Why stop only the safety sciences? Systematic reviews are the perfect tool to get an overview what has been published, what are our agreed conclusions, what are the gaps which we are mapping by this exercise where do we not have clear conclusions on a given topic. Every area, all sciences, all preclinical sciences would benefit from this type of assessment in a very similar way. And by setting standards and also developing automated tools to help such systematic reviews we can actually help preclinical sciences in general. So I hope you enjoyed the entire course and you will enjoy giving a bit of a perspective of how these things might develop over the next few years. And in the best case, you become part of it. You become part of the evidence-based toxicology collaboration, and sign up for the various activities we are doing. Thank you very much.